Nektar Therapeutics (NASDAQ:NKTR)

This Week’s Biggest Biotech Movers

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these ...
Read Full Story »

Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock

Nektar Therapeutics (NASDAQ: NKTR) shares were crushed on Wednesday after the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management ...
Read Full Story »

Why This Early-Stage Autoimmune and Chronic Inflamatory Trial May Be a Big Hit

Nektar Therapeutics (NASDAQ: NKTR) shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apollo, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target, TJX and More

Stocks were indicated to open lower on Tuesday with more concerns over Brexit and concerns that trade talks with China will not yield very much. The bull market is well ...
Read Full Story »

10 Stocks Getting Crushed After Earnings

It has been a wild and volatile week in the stock market. Reactions to trade war news, interest rate scares and even earnings have all played their part in creating ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Activision Blizzard, ANGI, Azul, Baidu, CommScope, E*Trade, Kraft Heinz, Symantec, Uber and More

Stocks have been volatile all week, but much of the losses from earlier in the week have been recovered. Stocks were indicated to open lower on Friday ahead of the ...
Read Full Story »

Tuesday’s Biggest Winners and Losers in the S&P 500

January 8, 2019: The S&P 500 closed up 1.0% at 2,574.42. The DJIA closed up 1.1% at 23,787.58. Separately, the Nasdaq closed up 1.1% at 6,897.00. Tuesday was a positive ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Arena Pharma, Autodesk, Coca-Cola, GE, Marvell, Monster Beverages, Nabors, Procter & Gamble and More

The futures traded slightly higher Thursday morning as the markets digested yesterday's upside move. Positive talk on trade and some more benign inflation data were seen as the key reasons ...
Read Full Story »

Monday’s Biggest Winners and Losers in the S&P 500

November 12, 2018: The S&P 500 closed down 2.0% at 2,726.32. The DJIA closed down 2.3% at 25,388.54. Separately, the Nasdaq closed down 2.8% at 7,200.87. Monday was a down ...
Read Full Story »

Tuesday’s Biggest Winners and Losers in the S&P 500

November 6, 2018: The S&P 500 closed up 0.6% at 2,755.46. The DJIA closed up 0.7% at 25,638.47. Separately, the Nasdaq closed up 0.6% at 7,375.96. Tuesday was a positive ...
Read Full Story »

Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration

Nektar Therapeutics (NASDAQ: NKTR) shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer Inc. (NYSE: PFE) to evaluate several combination regimens in multiple cancer ...
Read Full Story »

Monday’s Biggest Winners and Losers in the S&P 500

October 1, 2018: The S&P 500 closed up 0.4% at 2,924.81. The DJIA closed up 0.8% at 26,662.37. Separately, the Nasdaq closed flat at 8,037.30. Monday was a mixed day ...
Read Full Story »

Why Nektar Therapeutics Shares Are Tumbling

Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results were presented ...
Read Full Story »

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and ...
Read Full Story »

Jefferies Has 4 Red-Hot Growth Stocks to Buy Despite Volatility

One thing's for sure: if the last two weeks haven’t left some investors a little shell-shocked, then they are lying or they sold out in front of all the selling. ...
Read Full Story »